
    
      Patients will all receive oral doses of 1592U89 in combination with protocol specific current
      antiretroviral therapy. The treatment groups will be assigned based on each subject's
      previous NRTI experience.

      The study medication is self administered and all evaluations will be performed on an
      outpatient basis. Patients will be seen at day 0 and weeks 2, 4, 12, 16, 20 and 24.
    
  